Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) released its earnings results on Friday. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04, FiscalAI reports. The firm had revenue of $2.96 million during the quarter, compared to the consensus estimate of $1.00 million.
Here are the key takeaways from Milestone Pharmaceuticals’ conference call:
- CARDAMYST prescriptions rose 50% quarter over quarter to approximately 1,800, while unique prescribers increased to about 750. Commercial formulary coverage reached roughly two-thirds of covered lives, and third-quarter net product revenue grew to $1.0 million from $0.6 million in Q2.
- Milestone expects its cost-efficiency measures—including bringing its 45-person sales team in-house and focusing spending on higher-impact activities—to reduce operating expenses by about 30%. The company expects to complete the changes by Q1 2027, with approximately $2 million in one-time charges.
- Milestone said the cost reductions and an extension of its payment-in-kind interest period are expected to extend its cash runway into late 2028, through the anticipated ReVeRA-301 Phase III readout in the second half of 2028. The trial is enrolling patients in the U.S., Canada, and Europe.
- Third-quarter selling, general, and administrative expense rose to $24.2 million from $7.9 million a year earlier, primarily due to CARDAMYST launch costs; net loss widened to $25.8 million from $11.9 million. Management also noted that prescription growth remains gradual and expects possible seasonal pressure in Q1 as insurance out-of-pocket costs reset.
- Management views emergency-department and ambulance use as potential longer-term opportunities, but said operational hurdles make them a lower priority over the next 12–18 months. Medicare is also not expected to drive near-term prescription growth, with the company favoring selective coverage over broad Part D discounts.
Milestone Pharmaceuticals Stock Performance
NASDAQ MIST traded down $0.14 on Friday, hitting $0.52. 4,142,608 shares of the stock were exchanged, compared to its average volume of 1,227,676. The company has a debt-to-equity ratio of 3.25, a current ratio of 8.13 and a quick ratio of 7.92. The business’s fifty day moving average is $0.80 and its 200 day moving average is $1.31. Milestone Pharmaceuticals has a 52 week low of $0.50 and a 52 week high of $3.06. The company has a market capitalization of $64.74 million, a PE ratio of -0.75 and a beta of 1.07.
Latest Milestone Pharmaceuticals News
Here’s some of the latest news about MIST:
- Positive Sentiment: MIST reported a third-quarter loss of $0.18 per share, narrower than analysts’ expected $0.22 loss, and revenue of $2.96 million versus the $1.00 million consensus estimate. Zacks Q3 results
- Positive Sentiment: CARDAMYST product revenue reached about $1.0 million, up 73% from the prior quarter, with roughly 3,400 prescriptions and coverage across about two-thirds of commercially insured lives. CARDAMYST and runway update
- Negative Sentiment: The CFO and CMO have left the leadership team. Although cost reductions should conserve cash, the departures and the need to scale back spending may raise concerns about execution and commercialization. Cost-cutting and leadership update
Wall Street Analysts Forecast Growth
MIST has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, October 12th. HC Wainwright restated a “buy” rating on shares of Milestone Pharmaceuticals in a report on Thursday, September 3rd. Wall Street Zen upgraded shares of Milestone Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday. Finally, Cantor Fitzgerald started coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Milestone Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.40.
Check Out Our Latest Stock Report on Milestone Pharmaceuticals
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.
Read More
- Five stocks we like better than Milestone Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
